Intraperitoneal Therapy for Ovarian Cancer

Medientyp: E-Book

Titel: Intraperitoneal Therapy for Ovarian Cancer

Enthält: Intraperitoneal Therapy for Ovarian Cancer; Acknowledgment; Contents; 1: Introduction; References; 2: Current Chemotherapy of Ovarian Cancer; 2.1 Trials that Define Primary Treatment; 2.2 Optimal Integration of Taxanes; 2.3 Integration of a Third Cytotoxic Agent; 2.4 New Approaches Targeting the Mitotic Apparatus; 2.5 Development of Alternative Cytotoxic Agents; 2.6 Biologic Principles with an Impact on Primary Therapy; 2.7 Targeting Angiogenesis; 2.8 Chemotherapy Resistance; 2.9 Synthetic Lethal Strategies; 2.10 Discussion; References; 3: Principles of Intraperitoneal Chemotherapy
3.1 Introduction3.2 Rationale for the Delivery of Antineoplastic Agents by the IntraperitonealRoute as a Treatment for Intraperitoneal Malignan; 3.2.1 Anatomic Location of the Cancer; 3.2.2 General Physiology of the Peritoneal Cavity Relevant for Intraperitoneal Antineoplastic Drug Delivery; 3.2.3 Evidence of Concentration-Dependent Biological Activity of an Antineoplastic Agent; 3.3 Limitations of Intraperitoneal Antineoplastic Drug Delivery; 3.3.1 Local Toxicity of Antineoplastic Agents; 3.3.2 Adequacy of Drug Distribution
3.3.3 Limited Direct Penetration of Antineoplastic Agents into Tumor Masses3.3.4 Importance of Drug Delivery by Capillary Flow; 3.3.5 Other Relevant Issues Defining the Use of Intraperitoneal Chemotherapy; 3.4 Conclusion; References; 4: Intraperitoneal Chemotherapy:Phase III Trials; 4.1 Introduction; 4.2 SWOG 8501/GOG 0104/EST 3885; 4.3 GOG 0114/SWOG 9227/ECOG-GO 114; 4.4 GOG 0172; 4.5 Future Phase III IP Trials; 4.6 Conclusion; References; 5: Criteria for Using Intraperitoneal (IP) Chemotherapy for Advanced Ovarian Cancer; 5.1 Frontline Therapy; 5.1.1 Impact of the Size of Residual Disease
5.1.2 Impact of Chemical Debulking Prior to IP Therapy5.1.3 Impact of Disease Stage; 5.2 Consolidation Therapy; 5.2.1 Consolidation Therapy for Patients with no Residual Disease; 5.2.2 Consolidation Therapy for Patients with Minimal Residual Disease; 5.2.3 Impact of Retroperitoneal Disease; 5.2.4 Impact of Stage IV Disease; 5.2.5 Presence of Adhesions; 5.3 Conclusions; References; 6: Selection and Placement of Intraperitoneal Catheters for IP Chemotherapy for Ovarian Cancer; 6.1Introduction; 6.2Background on IP Catheters
6.3 Peritoneal Catheter Placement at Primary Surgery for Presumed Ovarian Cancer6.4 Radical Surgical Procedures; 6.5 Choice of Device and Catheter; 6.6 Technique for Placement at Laparotomy; 6.7 Prevention of Catheter Failures; 6.8 Prevention of Adhesions; 6.9 Delayed Insertion of Peritoneal Catheter; 6.10 Interventional Radiology Placement; 6.11 Removal of the Catheter; 6.12 Conclusions; References; 7: Selection of Drugs for Intraperitoneal Chemotherapy for Ovarian Cancer; 7.1 Introduction; 7.2 Pharmacologic Principles of Intraperitoneal Therapy
7.3 Relative Clearances and First Pass Metabolism

Beteiligte: Alberts, David S. [VerfasserIn]; Clouser, Mary C. [Sonstige Person, Familie und Körperschaft]; Hess, Lisa M. [Sonstige Person, Familie und Körperschaft]

Erschienen: Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg, 2010

Umfang: Online-Ressource (VIII, 154p. 18 illus., 12 illus. in color, digital)

Sprache: Englisch

DOI: 10.1007/978-3-642-12130-2

ISBN: 9783642121302

Identifikator:

RVK-Notation: XH 8415 : Therapie (medikamentöse, physikalische Rehabilitation)

Schlagwörter: Eierstockkrebs > Lokoregionäre Chemotherapie > Bauchhöhle
Eierstockkrebs > Intraperitoneale Applikation

Entstehung:

Anmerkungen: Includes bibliographical references and index

Beschreibung: Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: